Capital World Investors Boosts Stake in Regeneron Pharmaceuticals

The investment firm increased its holdings in the biopharmaceutical company by 1.6% in the third quarter.

Mar. 11, 2026 at 8:34am

Got story updates? Submit your updates here. ›

Capital World Investors, a major institutional investor, increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.6% in the third quarter. The fund now owns 1,998,366 shares of the biopharmaceutical company's stock, valued at approximately $1.12 billion.

Why it matters

Regeneron Pharmaceuticals is a leading biotech firm known for its innovative drug discovery technologies and pipeline of biologic therapies. Institutional investors like Capital World Investors closely monitor and adjust their positions in the company, which can signal broader market sentiment and expectations around Regeneron's future performance.

The details

According to a recent SEC filing, Capital World Investors purchased an additional 32,348 shares of Regeneron Pharmaceuticals during the third quarter. This increased the firm's total stake in the company to approximately 1.9% of outstanding shares. Regeneron is a prominent player in the biopharmaceutical industry, with a market capitalization of over $81 billion.

  • Capital World Investors increased its Regeneron Pharmaceuticals stake in the 3rd quarter of 2026.

The players

Capital World Investors

A major institutional investment firm that manages a diversified portfolio of stocks, including a significant position in Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The increased investment by Capital World Investors in Regeneron Pharmaceuticals reflects the firm's confidence in the biotech company's long-term growth potential and innovative drug pipeline. This move highlights the continued institutional interest in Regeneron as a leading player in the biopharmaceutical industry.